Table 2 Baseline characteristics of bio-naïve AS patients starting a first TNFi in 2006–2015
Baseline characteristics | 2006–2015 cohort | 2006–2010 subset-cohort |
|---|---|---|
Total number | 2590 | 1167 |
Sex, men (%) | 1827 (71) | 838 (72) |
Age, mean (sd) | 44 (13.2) | 44 (12.8) |
Disease duration | 16 (12.3) | 16 (11.8) |
csDMARD (concomitant use), n (%) | 634 (24) | 384 (33) |
NSAID (concomitant use), n (%) | 2136 (82) | 972 (83) |
Peripheral diseasea | 464 (18) | 195 (17) |
Type of TNFi | ||
Infliximab, n (%) | 910 (35) | 478 (41) |
Adalimumab, n (%) | 782 (30) | 405 (35) |
Golimumab, n (%) | 329 (13) | 9 (1) |
Etanercept, n (%) | 483 (19) | 273 (23) |
Certolizumab pegol, n (%) | 86 (3) | 2 (0) |
Extra-articular SpA manifestations | ||
Anterior uveitis, n (%) | 711 (27) | 308 (26) |
Psoriasis, n (%) | 156 (6) | 65 (6) |
Inflammatory bowel disease, n (%) | 179 (7) | 95 (8) |